黑料网

STOCK TITAN

Cassava Sciences Reports Q3 2024 Financial and Operating Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Cassava Sciences reported Q3 2024 financial results and provided updates on its Phase 3 clinical program for simufilam in Alzheimer's disease. The company maintains $149.0 million in cash with no debt, reporting a net loss of $27.9 million ($0.58 per share). The RETHINK-ALZ Phase 3 trial has completed with approximately 635 patients, while REFOCUS-ALZ has over 550 completers. Top-line data for RETHINK-ALZ is expected before end of 2024, with REFOCUS-ALZ results anticipated mid-2025. About 88% of Phase 3 completers have entered the open-label extension study, which now includes over 1,040 patients.

Cassava Sciences ha riportato i risultati finanziari del terzo trimestre 2024 e fornito aggiornamenti sul suo programma clinico di fase 3 per il simufilam nella malattia di Alzheimer. L'azienda mantiene 149,0 milioni di dollari in contante senza debiti, registrando una perdita netta di 27,9 milioni di dollari (0,58 dollari per azione). Lo studio clinico RETHINK-ALZ di fase 3 猫 stato completato con circa 635 pazienti, mentre REFOCUS-ALZ ha pi霉 di 550 pazienti che hanno completato lo studio. I dati principali per RETHINK-ALZ sono attesi entro la fine del 2024, mentre i risultati di REFOCUS-ALZ sono previsti per met脿 2025. Circa l'88% dei pazienti che hanno completato la fase 3 ha partecipato allo studio di estensione in aperto, che ora include oltre 1.040 pazienti.

Cassava Sciences report贸 los resultados financieros del tercer trimestre de 2024 y proporcion贸 actualizaciones sobre su programa cl铆nico de fase 3 para el simufilam en la enfermedad de Alzheimer. La empresa mantiene 149,0 millones de d贸lares en efectivo sin deudas, reportando una p茅rdida neta de 27,9 millones de d贸lares (0,58 d贸lares por acci贸n). El ensayo cl铆nico RETHINK-ALZ de fase 3 se ha completado con aproximadamente 635 pacientes, mientras que REFOCUS-ALZ tiene m谩s de 550 pacientes completadores. Se esperan los datos principales de RETHINK-ALZ antes de finalizar 2024, con resultados de REFOCUS-ALZ anticipados para mediados de 2025. Alrededor del 88% de los pacientes que completaron la fase 3 han ingresado al estudio de extensi贸n a etiqueta abierta, que ahora incluye a m谩s de 1,040 pacientes.

旃挫偓氚 靷澊鞏胳姢電 2024雲 3攵勱赴 鞛 瓴瓣臣毳 氚滍憸頃橁碃 鞎岇笭頃橃澊毹鸽硲 旃橂毳 鞙勴暅 鞁滊頃勲瀸鞚 3靸 鞛勳儊 頂勲攴鸽灗 鞐呺嵃鞚错姼毳 鞝滉车頄堨姷雼堧嫟. 鞚 須岇偓電 1鞏 4,900毵 雼煬鞚 順勱笀鞚 氤挫湢頃橁碃 鞛堨溂氅 攵毂勱皜 鞐嗢溂氅, 靾滌啇鞁れ澊 2,790毵 雼煬 (欤茧嫻 0.58雼煬)鞐 雼暅雼り碃 氤搓碃頄堨姷雼堧嫟. RETHINK-ALZ 3靸 鞁滍棙鞚 鞎 635氇呾潣 頇橃瀽鞕 頃粯 鞕勲霅橃棃鞙茧┌, REFOCUS-ALZ電 550氇 鞚挫儊鞚 頇橃瀽 鞕勳<鞛愲ゼ 氤挫湢頃橁碃 鞛堨姷雼堧嫟. RETHINK-ALZ鞚 欤检殧 雿办澊韯半姅 2024雲 毵 鞚挫爠鞐 鞓堨儊霅橂┌, REFOCUS-ALZ鞚 瓴瓣臣電 2025雲 欷戨皹鞐 鞓堨儊霅╇媹雼. 3靸 鞁滍棙鞚 毵堨箿 頇橃瀽鞚 鞎 88%臧 順勳灛 1,040氇 鞚挫儊鞚 頇橃瀽毳 韽暔頃橂姅 鞓ろ攬 霠堨澊敫 鞐办灔 鞐瓣惮鞐 彀胳棳頃橁碃 鞛堨姷雼堧嫟.

Cassava Sciences a publi茅 les r茅sultats financiers du troisi猫me trimestre 2024 et a fourni des mises 脿 jour sur son programme clinique de phase 3 pour le simufilam dans la maladie d'Alzheimer. L'entreprise dispose de 149,0 millions de dollars en liquidit茅s et n'a aucune dette, rapportant une perte nette de 27,9 millions de dollars (0,58 dollar par action). L'essai clinique RETHINK-ALZ de phase 3 a 茅t茅 achev茅 avec environ 635 patients, tandis que REFOCUS-ALZ compte plus de 550 participants qui ont termin茅 l'茅tude. Les donn茅es principales pour RETHINK-ALZ sont attendues avant la fin de 2024, avec des r茅sultats de REFOCUS-ALZ anticip茅s pour la mi-2025. Environ 88 % des patients de la phase 3 ont particip茅 脿 l'茅tude d'extension en ouvert, qui comprend maintenant plus de 1 040 patients.

Cassava Sciences hat die Finanzdaten des dritten Quartals 2024 ver枚ffentlicht und Updates zu seinem klinischen Programm der Phase 3 f眉r Simufilam bei Alzheimer bereitgestellt. Das Unternehmen h盲lt 149,0 Millionen Dollar in bar ohne Schulden und berichtete einen Nettverlust von 27,9 Millionen Dollar (0,58 Dollar pro Aktie). Die RETHINK-ALZ-Studie der Phase 3 wurde mit etwa 635 Patienten abgeschlossen, w盲hrend REFOCUS-ALZ 眉ber 550 Abschlusspatienten hat. Die Hauptdaten f眉r RETHINK-ALZ werden vor Ende 2024 erwartet, w盲hrend die Ergebnisse von REFOCUS-ALZ f眉r Mitte 2025 prognostiziert werden. Etwa 88 % der Patienten, die die Phase 3 abgeschlossen haben, haben an der offenen Verl盲ngerungsstudie teilgenommen, die jetzt 眉ber 1.040 Patienten umfasst.

Positive
  • Strong cash position of $149.0 million with no debt
  • High patient retention with 88% of Phase 3 completers entering open-label extension
  • Cash runway expected to support operations into 2026
  • R&D expenses decreased from $23.6M to $17.7M year-over-year
Negative
  • Net loss increased to $27.9M from $25.7M year-over-year
  • G&A expenses tripled to $12.9M from $4.3M year-over-year
  • Pending $40M SEC investigation settlement payment
  • Phase 3 trials experiencing 21-25% dropout rates

Insights

Cassava Sciences' Q3 report reveals critical financial positioning ahead of key Phase 3 readouts. With $149.0 million cash position and no debt, operations are funded into 2026, providing runway beyond both Phase 3 trial readouts. The $27.9 million quarterly net loss ($0.58/share) and projected year-end cash of $117-127 million indicate careful cash management despite significant R&D investments.

Notable is the 88% patient retention rate in the open-label extension study, suggesting strong participant confidence. The 21-25% dropout rates in Phase 3 trials align with industry standards. The pending $40 million SEC settlement and increased G&A expenses to $12.9 million represent significant but manageable financial obligations.

The completion of RETHINK-ALZ patient visits marks a important milestone, with top-line data expected by year-end 2024. The trial's robust design includes approximately 635 completers, providing substantial statistical power. The DSMB's third consecutive recommendation to continue without modifications indicates a favorable safety profile.

The decision to add cognition and plasma biomarker monitoring to the OLE study is strategically important, potentially providing valuable long-term efficacy data. With 1,040 patients in the OLE study, this represents one of the larger long-term datasets for an Alzheimer's treatment, offering insights into simufilam's sustained effects and safety profile.

  • Top-line Data for RETHINK-ALZ 52-week Phase 3 trial Expected Before the End of 2024
  • $149.0 Million in Cash and Cash Equivalents at September 30, 2024. Expected To Support Operations Into 2026
  • Conference Webcast Scheduled for Today at 8:30AM ET

AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer鈥檚 disease, today reported financial results for the third quarter ended September 30, 2024.

鈥淲e look forward to the release of top-line results from RETHINK-ALZ, our first Phase 3 trial for simulfilam, by the end of 2024,鈥 said Rick Barry, President and Chief Executive Officer. 鈥淭his will represent the culmination of three-plus years of concerted effort by our clinical team, principal investigators, patients and their caregivers.鈥

Current Updates on Phase 3 Clinical Program
Background - Our Phase 3 program consists of two global, double-blind, randomized, placebo-controlled studies of simufilam, an investigational agent in development for the potential treatment of patients with mild-to-moderate Alzheimer鈥檚 disease (鈥淎lzheimer鈥檚鈥 or 鈥淎D鈥). The program鈥檚 goal is to evaluate the overall safety and efficacy of oral simufilam, administered twice-daily, versus placebo, in a large population of people with Alzheimer鈥檚 disease over 12 and 18 months.

The target study population is people with mild-to-moderate Alzheimer鈥檚 (mini-mental state examination, (MMSE) score of 16-27) who are biomarker-positive for Alzheimer鈥檚 disease pathology and who meet other inclusion/exclusion eligibility criteria of the study protocols.

Phase 3 Trials 鈥 Our first Phase 3 study, RETHINK-ALZ (NCT04994483), is designed to evaluate the safety and efficacy of simufilam 100 mg tablets administered twice-daily versus matching placebo over 52 weeks.听Our second Phase 3 study, REFOCUS-ALZ (NCT05026177), is designed to evaluate the safety and efficacy of two doses of oral simufilam tablets, 100 mg and 50 mg, administered twice-daily, versus matching placebo, over 76 weeks. Clinical sites are in the United States, Canada, Puerto Rico, Australia, and South Korea.

Patient Enrollment 鈥 Both Phase 3 studies are fully enrolled. Approximately 1,900 patients are randomized听in these studies, with approximately 800 patients randomized into RETHINK-ALZ and approximately 1,100 patients randomized into REFOCUS-ALZ. Approximately 90% of patients are recruited from clinical sites in the U.S. and Canada. The overall drop-out rate was 21% for RETHINK-ALZ and has been 25% for REFOCUS-ALZ; these numbers are generally consistent with expectations.

Patient Completion 鈥 The Last Patient/Last Visit (LPLV) occurred several weeks ago for the RETHINK-ALZ study, with approximately 635 patients completed. To date, over 550 patients have completed the REFOCUS-ALZ study, for a total of over 1,185 completers.

Data and Safety Monitoring Board (DSMB) 鈥 The DSMB is composed of independent clinical research experts who periodically review interim patient safety data. Following a third听routine, scheduled meeting听in September 2024, the DSMB recommended that both of our听Phase 3 studies continue as planned, without modification. This was consistent with recommendations of the DSMB following meetings in September 2023 and March 2024.

Co-primary Efficacy Outcomes 鈥 The pre-specified efficacy endpoints for the Phase 3 studies are Alzheimer鈥檚 Disease Assessment Scale-Cognitive subscale 12 (ADAS-Cog12), a cognitive scale, and Alzheimer鈥檚 Disease Cooperative Study 鈥 Activities of Daily Living subscale, (ADCS-ADL), a functional scale.

Phase 3 Efficacy Results 鈥 All efficacy data from our Phase 3 program remain blinded. No interim analyses on efficacy outcomes are planned. We expect to report top-line data for RETHINK-ALZ before the end of 2024. We anticipate a top-line data readout for REFOCUS-ALZ approximately mid-year 2025.

Open-label Extension Study 鈥 This study is designed to provide no-cost access to oral simufilam to Alzheimer鈥檚 patients who have successfully completed a Phase 3 study of simufilam and who meet other entry criteria. Approximately 88% of patients who have completed treatment in one of the two Phase 3 studies, RETHINK-ALZ or REFOCUS-ALZ, have opted to enter the open-label extension (OLE) study. To date, over 1,040 patients have entered the OLE study. The OLE study is intended to continue for up to 36 months or until a new drug application for simufilam has been reviewed by FDA. Cassava also plans to add cognition and plasma biomarker monitoring to its OLE trial for patients who have completed either of the two Phase 3 trials, in order to gather additional long-term data on the potential impact of simufilam treatment.

Financial Results for Third Quarter 2024

  • At September 30, 2024, cash and cash equivalents were $149.0 million. The Company has no debt.
  • Net loss was $27.9 million or $0.58 per share. This compares to a net loss of $25.7 million, or $0.61 per share, for the same period in 2023.
  • Net cash used in operations was $55.7 million during the first nine months of 2024.
  • Net cash used in operations for second half 2024 is expected to be $40 to $50 million, consistent with previous guidance. In addition, the Company intends to pay a previously announced $40 million SEC investigation settlement, which has been placed in escrow and excluded from cash and cash equivalents. The Company estimates cash and cash equivalents at year-end 2024 in a range from $117 to $127 million.
  • Research and development (R&D) expenses were $17.7 million. This compared to $23.6 million for the same period in 2023. R&D expenses decreased due primarily to the completion of patient screening and enrollment for our Phase 3 clinical program in the fall of 2023. Patients are continually听completing the Phase 3 program and a portion of completers are enrolling in the lower听cost听open-label extension study. These听decreases were partially offset by an increase in stock-based compensation expense due to new grant awards in the third quarter of听2024.
  • General and administrative (G&A) expenses were $12.9 million. This compared to $4.3 million for the same period in 2023. G&A expenses increased significantly due primarily to听higher legal related expenses, increased compensation costs, including severance, as well as an increase in stock-based compensation expense due to new grant awards in late 2023 and 2024.

Webcast Details
Date: Thursday, November 7th Time: 8:30 a.m. Eastern Time
Audio Webcast:
Or

About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer鈥檚 disease.

Simufilam is an investigational oral, small molecule drug candidate currently being evaluated in two Phase 3 clinical trials for the potential treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain.听Cassava Sciences believes that simufilam interrupts amyloid-尾42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

For more information, please visit:

For More Information Contact:

Investors
Sandya von der Weid

Media
Sitrick And Company

Company
Eric Schoen, Chief Financial Officer
(512) 501-2450

Cautionary Note Regarding Forward-Looking Statements:
This news release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that may include but are not limited to statements regarding: our ability to extend our existing open-label extension trials, as contemplated or at all; the design, scope, conduct, continuation, completion, intended purpose, or future results of our on-going Phase 3 program of simufilam in patients with Alzheimer's disease; the timing of anticipated milestones; the assessment of interim safety data for the Phase 3 program at prior DSMB meetings; the treatment of people with Alzheimer鈥檚 disease the safety or efficacy of simufilam in people with Alzheimer鈥檚 disease dementia; expected cash balances and cash use in future periods; comments made by our employees regarding simufilam, drug effects, and the treatment of Alzheimer鈥檚 disease; and potential benefits, if any, of our product candidates. These statements may be identified by words such as 鈥渁nticipate鈥, 鈥渂elieve鈥, 鈥渃ould鈥, 鈥渆xpect鈥, 鈥渇orecast鈥, 鈥渋ntend鈥, 鈥渕ay鈥, 鈥減lan鈥, 鈥減ossible鈥, 鈥減otential鈥, 鈥渨ill鈥, and other words and terms of similar meaning.

Such statements are based largely on our current expectations and projections about future events. Such statements speak only as of the date of this news release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, those risks relating to the ability to conduct or complete clinical studies on expected timelines, the ability to demonstrate the specificity, safety, efficacy or potential health benefits of our product candidates, the apparent ability of simufilam to favor patients with mild Alzheimer鈥檚 disease; the apparent safety or tolerance of simufilam in our open-label clinical trials; our current expectations regarding timing of clinical data for our Phase 3 studies; any expected clinical results of Phase 3 studies; the treatment of people with Alzheimer鈥檚 disease; and comments made by our employees regarding simufilam, drug effects, and the treatment of Alzheimer鈥檚 disease; potential benefits, if any, of our product candidates and including those described in the section entitled 鈥淩isk Factors鈥 in our Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Report on Form 10-Q for the period ended June 30, 2024, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this news release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility for updating or revising any forward-looking statements. For further information regarding these and other risks related to our business, investors should consult our filings with the SEC, which are available on the SEC's website at .

All of our pharmaceutical assets under development are investigational product candidates. These have not been approved for use in any medical indication by any regulatory authority in any jurisdiction and their safety, efficacy or other desirable attributes, if any, have not been established in any patient population. Consequently, none of our product candidates is approved or available for sale anywhere in the world.

Our clinical results from earlier-stage clinical trials may not be indicative of future results from later-stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or any scientific data we present or publish.

We are in the business of new drug discovery and development. Our research and development activities are long, complex, costly and involve a high degree of risk. Holders of our common stock should carefully read our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q in their entirety, including the risk factors therein. Because risk is fundamental to the process of drug discovery and development, you are cautioned to not invest in our publicly traded securities unless you are prepared to sustain a total loss of the money you have invested.

鈥 Financial Tables Follow 鈥

CASSAVA SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share amounts)
Three months ended September 30,Nine months ended September 30,
2024202320242023
Operating expenses
Research and development$17,676$23,603$49,107$70,692
General and administrative12,9474,27662,85212,476
Total operating expenses30,62327,879111,95983,168
Operating loss(30,623)(27,879)(111,959)(83,168)
Interest income2,6182,0056,7106,254
Other income, net62223321616
Gain from change in fair value of warrant liabilities108,183
Net income (loss)$(27,943)$(25,651)$3,255$(76,298)
Net income (loss) per share, basic$(0.58)$(0.61)$0.07$(1.82)
Net income (loss) per share, diluted(0.58)(0.61)(0.88)(1.82)
Weighted-average shares used in computing net income (loss) per share, basic47,97642,00245,73441,845
Weighted-average shares used in computing net income (loss) per share, diluted47,97642,00246,10141,845


CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited, in thousands)
September 30,
2024
December 31,
2023
Assets
Current assets
Cash and cash equivalents$148,978$121,136
Restricted cash40,000
Prepaid expenses and other current assets13,5718,497
Total current assets202,549129,633
Property and equipment, net21,13521,854
Intangible assets, net69176
Total assets$223,753$151,663
Liabilities and stockholders' equity
Current liabilities
Accounts payable and accrued expenses$52,244$10,573
Accrued development expense2,5433,037
Accrued compensation and benefits1,950200
Other accrued liabilities297385
Total current liabilities57,03414,195
Other non- current liabilities80
Total liabilities57,11414,195
Stockholders' equity
Common Stock and additional paid-in-capital544,153518,237
Accumulated deficit(377,514)(380,769)
Total stockholders' equity166,639137,468
Total liabilities and stockholders' equity$223,753$151,663

FAQ

When will Cassava Sciences (SAVA) release RETHINK-ALZ Phase 3 trial results?

Cassava Sciences expects to release top-line results from the RETHINK-ALZ Phase 3 trial before the end of 2024.

What was Cassava Sciences' (SAVA) Q3 2024 net loss?

Cassava Sciences reported a net loss of $27.9 million, or $0.58 per share, for Q3 2024.

How many patients completed Cassava Sciences' (SAVA) Phase 3 trials?

Approximately 635 patients completed the RETHINK-ALZ study, and over 550 patients have completed the REFOCUS-ALZ study, totaling over 1,185 completers.

What is Cassava Sciences' (SAVA) current cash position in Q3 2024?

Cassava Sciences reported $149.0 million in cash and cash equivalents as of September 30, 2024, with no debt.

Cassava Sciences, Inc.

NASDAQ:SAVA

SAVA Rankings

SAVA Latest News

SAVA Stock Data

138.44M
42.04M
12.65%
29.93%
36.62%
Biotechnology
Pharmaceutical Preparations
United States of America
AUSTIN